Scribd
Upload
114 views1 page

Hidradenitis Suppurativa Infographic 1686324709

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurring nodules, abscesses, and pus-discharging tunnels, especially in the armpit and groin areas. It affects approximately 1 in 100 people, more commonly women. HS can take 10 years on average to diagnose and causes pain, mental health issues like depression, missed work, social stigma, and intimacy problems. Effective long-term treatment options are limited.

Uploaded by

juan.fernandezz8319
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
114 views1 page

Hidradenitis Suppurativa Infographic 1686324709

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurring nodules, abscesses, and pus-discharging tunnels, especially in the armpit and groin areas. It affects approximately 1 in 100 people, more commonly women. HS can take 10 years on average to diagnose and causes pain, mental health issues like depression, missed work, social stigma, and intimacy problems. Effective long-term treatment options are limited.

Uploaded by

juan.fernandezz8319
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

What is HS and how does it affect

the people who live with it?


What is hidradenitis suppurativa?

1in
Hidradenitis suppurativa (HS) is a chronic Estimates indicate that HS affects
and painful inflammatory skin condition.1 It is around 1 in 100 people (in most
characterised by recurring nodules, abscesses countries for which data are available).1
HS also appears to be more than twice

100
and pus-discharging tunnels that can result in
odour.1 Although much is still unknown about as common in women than it is in
HS, international efforts are underway to men, based on estimates from four regions
better understand its epidemiology.2 in the United States.3

Key challenges
Effective treatment options are On average, people with HS
It can take on average limited, meaning that nearly report missing at least

10 50% 2
up to

years of people days


for a person with HS to receive with HS are dissatisfied of work per month
an accurate diagnosis.4* with their current treatment.1 4* due to their HS.5**

Living with HS

MENTAL HEALTH STIGMA


More than 1 in 3 people The physical symptoms
living with HS report of HS can cause feelings of
having depression, self-consciousness,
anxiety or both, while embarrassment and
approximately 1 in 11 has shame.4*
considered or attempted
suicide.4*
SOCIAL AND FAMILY LIFE
People living with HS often
WORK
feel unable to
HS may result in participate in family
absence from work activities, social
and unemployment.5** 6 interactions and
physical activities.4* 5** 6

INTIMACY ‘ I used to be ashamed of my HS


The physical symptoms but being able to talk about it
of HS can lead to
now is so important for me.’
anxiety around
being intimate and Bente Villumsen
how the other person Danish Hidradenitis Suppurativa
Patients’ Association
might react.5**

The impact of HS on the lives of people affected will be explored


further in an upcoming international report.

Funding disclaimer
This infographic was developed as part of a project which is led by The Health Policy Partnership (HPP) with guidance from
a multidisciplinary steering committee. HPP was commissioned by UCB, which initiated and is funding the project. UCB
reviews all outputs, but editorial control lies with the steering committee. Contributing experts are not paid for their time.
References
* Based on international survey data, with 1,299 participants in a survey from 2020.4
** Based on international survey data, with 537 participants in a survey from 2022.5
1. Sabat R, Jemec GBE, Matusiak Ł, et al. 2020. Nat Rev Dis Primers 6(18): 1-20
2. Global Hidradenitis Suppurativa Atlas. 2022. https://ghisa.org/
3. Garg A, Kirby JS, Lavian J, et al. 2017. JAMA Dermatol 153(8): 760-64
4. Garg A, Neuren E, Cha D, et al. 2020. J Am Acad Dermatol 82(2): 366-76
5. Kashetsky N, Mukovozov IM, Pereira J, et al. 2022. Clin Exp Dermatol 47(1): 72-79
6. Delany E, Gormley G, Hughes R, et al. 2018. J Eur Acad Dermatol Venereol 32(3): 467-73

© UCB Biopharma SRL, 2023. All rights reserved. | GL-N-DA-HS-2300026 | Date of preparation: May 2023

You might also like